Ripasudil drops before Descemet stripping surgery in Fuchs disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether Glanatec (ripasudil) eye drops help patients with Fuchs endothelial dystrophy get better results from Descemet stripping surgery. It may help improve vision and reduce symptoms for people whose vision problems come mainly from the Fuchs changes in the cornea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read, understand, and sign the informed consent form
- You are age 30 up to (but not including) 91
- You have Fuchs endothelial dystrophy, confirmed by the study eye doctor (including special cornea imaging)
- Your eye has an artificial lens placed inside (pseudophakic), with the lens supported in specific ways
- Your vision is 20/40 or worse in the study eye, and the doctor feels the main cause is Fuchs “central guttae,” not cataract or other cornea swelling
- Your cornea endothelial cell count is above 1000 cells/mm², and the outer (peripheral) cornea is clear
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ripasudil eye drops can help people with Fuchs' endothelial dystrophy (FED) during and after cataract surgery. It aims to see if the drops protect the eye's inner layer and improve recovery.
This Phase 3 trial compares outcomes from two cornea transplant procedures in people with FECD, a disease that makes the cornea swell and affect vision. It may help you and others by identifying which approach best supports clear vision and stable corneal thickness after surgery.
This study follows people with Fuchs' endothelial corneal dystrophy over time to see how the condition changes and how it relates to their genes. It aims to help doctors better predict and manage the disease.
This trial tests a new corneal implant to treat corneal swelling caused by Fuchs' dystrophy or after cataract surgery. It aims to improve vision and reduce the need for a full corneal transplant.
This trial looks at how to manage medicine around DMEK corneal transplant surgery to improve eye outcomes and safety. It may help people having this specific type of cornea transplant by testing an approach in the time after surgery.
This Phase 1 study tests whether EO2002 eye drops are safe and well tolerated in people with painful corneal swelling caused by the cornea’s inner lining not working well. It focuses on safety first, but your eye symptoms and vision may be monitored to see how you respond.
Hear when a new Fuchs' Endothelial Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.